China NMPA Approves IND for Equecabtagene Autoleucel

China NMPA approves IASO Bio’s IND for Equecabtagene Autoleucel in second- and third-line treatment of multiple myeloma

Overview

IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, announced that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for Equecabtagene Autoleucel (IASO Bio R&D code: CT103A), a self-developed fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) autologous T-cell injection, for an expanded indication in treating relapsed and/or refractory multiple myeloma (R/RMM) patients who have undergone 1-2 lines of prior therapies and are refractory to lenalidomide.

New Drug Application of Fucaso

• The New Drug Application (NDA) for Fucaso (Equecabtagene Autoleucel) was approved by NMPA for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received =3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent on June 30, 2023. 

Study Behind Approval 

• The NDA approval was based on the data from the pivotal FUMANBA-1 study (CTR20192510, NCT05066646) conducted at multiple sites in China. 
• According to the updated long-term follow-up data of the study published at the 2023 International Myeloma Society (IMS) Annual Meeting, as of December 31, 2022, among the 103 efficacy-evaluable patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%; in 91 participants without prior CAR-T therapy, ORR was 98.9%, 82.4% of patients reaching sCR/CR, and the 12-month progression-free survival (PFS) rate was 85.5%; 94.2% (97/103) of patients achieved minimal residual disease (MRD) negativity, and all sCR/CR patients achieved MRD negativity. 
• Among the 105 participants, only one experienced = Grade 3 cytokine release syndrome (CRS), with no = Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS). 
• Pharmacokinetics indicated that Equecabtagene Autoleucel persisted in vivo, with gene copy numbers detectable in 40% of participants at 24 months after infusion.

Multiple Myeloma

• Multiple myeloma (MM), a prevalent hematological malignancy, is marked by abnormal proliferation of clonal plasma cells. 
• For treatment-naïve MM patients, common first-line treatments include multiple-drug induction therapy, consolidation therapy, and maintenance therapy, as well as autologous stem cell transplantation (ASCT). 
• Despite initial remission, most patients will inevitably enter the relapsed or refractory stage, with no known cure to date.

Significance of CAR-T therapy

• According to the relevant study results published in the New England Journal of Medicine, CAR-T therapy significantly prolonged PFS and improved clinical response as compared with standard regimens in patients with relapsed/refractory multiple myeloma who had received 2-4 regimens previously. 
• In patients with lenalidomide-refractory, relapsed and refractory multiple myeloma who had received 1-3 previous therapies, the risk of disease progression or death was lower in those treated with CAR-T therapy than in those with standard care.

Case History Around World

• Data from Globocan indicates a rise in new MM cases in China from 20,066 in 2018 to 30,300 in 2022, and is projected to further rise to an anticipated 37,082 by 2030. 
• Similarly, new MM cases in the United States increased from 25,962 in 2018 to 32,258 in 2022, and is projected to reach 38,000 by 2030. 
• Worldwide, new MM cases increased from 159,985 in 2018 to 187,952 in 2022, and is projected to increase to 231,284 by 2030.

Words from CEO: IASO Bio

Jinhua Zhang, founder, chairman, and chief executive officer of IASO Bio, stated, ""The NMPA's IND approval for Equecabtagene Autoleucel in second- and third-line R/RMM treatment marks a pivotal advancement in its clinical journey. Evidence suggests that earlier CAR-T therapy in R/RMM patients leads to improved survival outcome. Given the compelling efficacy and safety profile demonstrated in previous clinical studies, Equecabtagene Autoleucel is poised to address significant unmet needs in early-stage MM treatment. We are eager to commence clinical enrollment, aiming to extend the benefits of this innovative therapy to more patients experiencing early relapse.""

About IASO Bio

• IASO Bio is a biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. 
• Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!